Guideline-adherent therapy in patients with cardiovascular diseases in Taiwan

Journal of the Formosan Medical Association

Volumn 114, Issue 10, 2015, Pages 1000-1007

  Jeng, Jiann Shing ^a   Yin, Wei Hsian ^b,c   Huang, Chin Chou ^c,d   Chuang, Shao Yuan ^e   Yeh, Hung I ^f   Fang, Ching Chang ^g   Lin, Tsung Hsien ^h   Wang, Kuo Yang ^i,j   Tseng, Wei Kung ^k,l   Huang, Lien Chi ^m   Ueng, Kwo Chang ^j,n   Hsieh, I Chang ^o   Li, Yi Heng ^p   Pan, Wen Harn ^e   Wu, Chau Chung ^a,q   Chen, Jaw Wen ^c,d  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b CHENG HSIN GENERAL HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^e NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^f MACKAY MEMORIAL HOSPITAL   (Taiwan)

^g TAINAN MUNICIPAL HOSPITAL   (Taiwan)

^h KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

ⁱ TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^j CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^k I SHOU UNIVERSITY   (Taiwan)

^l E DA HOSPITAL   (Taiwan)

^m TAIPEI HOSPITAL   (Taiwan)

ⁿ CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^o CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^p NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^q NATIONAL TAIWAN UNIVERSITY   (Taiwan)

more..

Author keywords

Adherence; Cerebrovascular disease; Coronary artery disease; Hypertension; Lipids

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CILOSTAZOL; CLOPIDOGREL; DIPYRIDAMOLE; DIURETIC AGENT; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIPID; LIPOPROTEIN; ORAL ANTIDIABETIC AGENT; TICLOPIDINE;

AGED; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL PRACTICE; COHORT ANALYSIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FEMALE; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRACTICE GUIDELINE; RISK FACTOR; TAIWAN; BLOOD; BLOOD PRESSURE; CEREBROVASCULAR DISORDERS; CLINICAL TRIAL; COMORBIDITY; COMPLICATION; DRUG EFFECTS; MIDDLE AGED; PROTOCOL COMPLIANCE; STATISTICAL MODEL;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CEREBROVASCULAR DISORDERS; COHORT STUDIES; COMORBIDITY; CORONARY ARTERY DISEASE; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYPERTENSION; LIPIDS; LOGISTIC MODELS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; TAIWAN;

EID: 84943355629     PISSN: 09296646     EISSN: 18760821     Source Type: Journal    
DOI: 10.1016/j.jfma.2013.10.007     Document Type: Article

References (30)

1. Mathers C.D., Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006, 3:e442.
2. Danaei G., Finucane M.M., Lin J.K., Singh G.M., Paciorek C.J., Cowan M.J., et al. National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5.4 million participants. Lancet 2011, 377:568-577.
3. Farzadfar F., Finucane M.M., Danaei G., Pelizzari P.M., Cowan M.J., Paciorek C.J., et al. National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3.0 million participants. Lancet 2011, 377:578-586.
4. Smith S.C., Collins A., Ferrari R., Holmes D.R., Logstrup S., McGhie D.V., et al. Our time: a call to save preventable death from cardiovascular disease (heart disease and stroke). Circulation 2012, 126:2769-2775.
5. Labarthe D.R., Dunbar S.B. Global cardiovascular health promotion and disease prevention: 2011 and beyond. Circulation 2012, 125:2667-2676.
6. Law M.R., Morris J.K., Wald N.J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009, 338:b1665.
7. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376:1670-1681. Cholesterol Treatment Trialists' (CTT) Collaboration.
8. Palnum K.H., Mehnert F., Andersen G., Ingeman A., Krog B.R., Bartels P.D., et al. Use of secondary medical prophylaxis and clinical outcome among patients with ischemic stroke: a nationwide follow-up study. Stroke 2012, 43:802-807.
9. Bhatt D.L., Steg P.G., Ohman E.M., Hirsch A.T., Ikeda Y., Mas J.L., et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006, 295:180-189.
10. Cacoub P.P., Zeymer U., Limbourg T., Baumgartner I., Poldermans D., Röther J., et al. Effects of adherence to guidelines for the control of major cardiovascular risk factors on outcomes in the REduction of Atherothrombosis for Continued Health (REACH) Registry Europe. Heart 2011, 97:660-667.
11. Mendis S., Abegunde D., Yusuf S., Ebrahim S., Shaper G., Ghannem H., et al. WHO study on Prevention of REcurrences of Myocardial Infarction and StrokE (WHO-PREMISE). Bull World Health Organ 2005, 83:820-829.
12. Saposnik G., Goodman S.G., Leiter L.A., Yan R.T., Fitchett D.H., Bayer N.H., et al. Applying the evidence: do patients with stroke, coronary artery disease, or both achieve similar treatment goals?. Stroke 2009, 40:1417-1424.
13. Mechtouff L., Touzé E., Steg P.G., Ohman E.M., Goto S., Hirsch A.T., et al. Worse blood pressure control in patients with cerebrovascular or peripheral arterial disease compared with coronary artery disease. J Intern Med 2010, 267:621-633.
14. Heeley E., Anderson C., Patel A., Cass A., Peiris D., Weekes A., et al. Disparities between prescribing of secondary prevention therapies for stroke and coronary artery disease in general practice. Int J Stroke 2012, 7:649-654.
15. Hsieh F.I., Lien L.M., Chen S.T., Bai C.H., Sun M.C., Tseng H.P., et al. AHA/ASA Get With The Guidelines-Stroke performance indicators: surveillance of stroke care in the Taiwan Stroke Registry: Get With the Guidelines-Stroke in Taiwan. Circulation 2010, 122:1116-1123.
16. Simpson C.R., Wilson C., Hannaford P.C., Williams D. Evidence for age and sex differences in the secondary prevention of stroke in Scottish primary care. Stroke 2005, 36:1771-1775.
17. Morrell J., Zeymer U., Baumgartner I., Limbourg T., Röther J., Bhatt D.L., et al. Differences in management and outcomes between male and female patients with atherothrombotic disease: results from the REACH Registry in Europe. Eur J Cardiovasc Prev Rehabil 2011, 18:270-277.
18. Yin W.H., Wu C.C., Chen J.W. Registry of lipid control and the use of lipid-lowering drugs for secondary prevention of cardiovascular events in patients with established atherosclerotic disease in Taiwan: rationality and methods. Int J Gerontol 2012, 6:241-246. on behalf of the Taiwanese Secondary Prevention for patients with AtheRosCLErotic disease (T-SPARCLE) Registry Investigators.
19. Smith S.C., Benjamin E.J., Bonow R.O., Braun L.T., Creager M.A., Franklin B.A., et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011, 124:2458-2473.
20. Furie K.L., Kasner S.E., Adams R.J., Albers G.W., Bush R.L., Fagan S.C., et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011, 42:227-276.
21. Davis S.M., Donnan G.A. Secondary prevention after ischemic stroke or transient ischemic attack. N Engl J Med 2012, 366:1914-1922.
22. Prugger C., Keil U., Wellmann J., de Bacquer D., de Backer G., Ambrosio G.B., et al. Blood pressure control and knowledge of target blood pressure in coronary patients across Europe: results from the EUROASPIRE III survey. J Hypertens 2011, 29:1641-1648.
23. Raine R., Wong W., Ambler G., Hardoon S., Petersen I., Morris R., et al. Sociodemographic variations in the contribution of secondary drug prevention to stroke survival at middle and older ages: cohort study. BMJ 2009, 338:b1279.
24. Ovbiagele B., Saver J.L., Bang H., Chambless L.E., Nassief A., Minuk J., et al. Statin treatment and adherence to national cholesterol guidelines after ischemic stroke. Neurology 2006, 66:1164-1170.
25. Waters D.D., Brotons C., Chiang C.W., Ferrières J., Foody J., Jukema J.W., et al. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation 2009, 120:28-34.
26. Stroebele N., Müller-Riemenschneider F., Nolte C.H., Müller-Nordhorn J., Bockelbrink A., Willich S.N. Knowledge of risk factors, and warning signs of stroke: a systematic review from a gender perspective. Int J Stroke 2011, 6:60-66.
27. Chandratheva A., Lasserson D.S., Geraghty O.C., Rothwell P.M. Oxford Vascular Study. Population-based study of behavior immediately after transient ischemic attack and minor stroke in 1000 consecutive patients: lessons for public education. Stroke 2010, 41:1108-1114.
28. Selim M.H., Molina C.A. High-dose statin for every stroke: the good, the bad, and the unknown. Stroke 2012, 43:1996-1997.
29. Reeves M.J., Fonarow G.C., Zhao X., Smith E.E., Schwamm L.H. Get With The Guidelines-Stroke Steering Committee Investigators. Quality of care in women with ischemic stroke in the GWTG program. Stroke 2009, 40:1127-1133.
30. Gall S.L., Donnan G., Dewey H.M., Macdonell R., Sturm J., Gilligan A., et al. Sex differences in presentation, severity, and management of stroke in a population-based study. Neurology 2010, 74:975-981.